Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.

Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.

While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

Shionogi is acquiring IntraBio for $2 billion, Gate Bioscience expands its collaboration with Eli Lilly, and Alector licenses Al050 to Genentech.

The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.

Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.